Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Home Knowledge Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

About this article

Date

Sep 6, 2016

Summary

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.

Share this on